PPT-C-SWIFT Study: elbasvir/grazoprevir + SOF

in genotypes 1 or 3 with or without cirrhosis gt 18 years Chronic HCV infection Genotype 1 or 3 HCV RNA gt 10 000 IU ml Treatmentnaïve Cirrhosis assessed by liver biopsy or noninvasive tests. 400/100 mg . qd. N = 500. N = 100. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 4, 5 or 6. Naïve or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. grazoprevir. . + . elbasvir. . in genotype 1 with Child-Pugh B cirrhosis. Jacobson IM. . EASL 2015, Abs. O008. Design. Child-Pugh B. GZR . 100 mg + . EBR . 50 mg. GZR 50 mg + EBR 50 mg. Non-cirrhotic. 2 3 Online.Swift/Ehrenpreis Centre for Swift Studies, M Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. D : . grazoprevir. . + . elbasvir. + RBV in genotype 3. C-WORTHY/D. Gane. . E. EASL 2015, Abs. . P0776. GZR + EBR + RBV. GZR + EBR + RBV. N = 21. N = 20. Design. W12. W18. SVR. 12. >. 18 years. 400/100/100 mg QD. N = 501. N = 440. W8. SOF/VEL 400/100 mg QD. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. Treatment-naïve or . IFN-experienced. Compensated cirrhosis **. allowed . Open-label. Chronic HCV infection. Genotype 1 . Failure to achieve SVR. 12. . on a short-course of 1. st. line. LDV/SOF-containing regimen . No cirrhosis. N = 34. SVR. 12. Co-formulated ledipasvir-sofosbuvir (LDV 90 mg/SOF 400 mg) : 1 pill qd. 400/100/100 mg QD. N = 263. N = 152. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. NS5A inhibitor-experienced . for ≥ 4 weeks (exclusion if . discontinued due to an adverse. Randomisation. 1 : 1. 18-70 years. HCV genotype 1. Naïve or pre-treated. with IFN-based regimen. No cirrhosis. HCV RNA ≥ . 10.000 . IU. /ml. No prior therapy with PI. No HBV or HIV co-infection. OPTIMIST-1 Study: SMV SOF for genotype 1. C-EDGE Treatment Naïve (TN). Phase 3. . Treatment. . Naïve. Zeuzem. S, . et al. . Ann Intern Med. 2015;163:1-13.. Source: . Zeuzem. S, et al. Ann Intern Med. 2015;163:1-13. .. Elbasvir-Grazoprevir. born on December . 13. th. in . Wyoming, Pennsylvania. . When . she was . little . she . grew up on a . Christmas tree . farm, . and on the holidays she helped sell . them. . S. he has a younger brother named . Biography. Born December 13, 1989. In Wyomissing, PA . To Andrea and Scott Swift. Younger brother Austin Swift. Grew up on a Christmas Tree farm in Pennsylvania. Moved to Hendersonville, TN to further music career.. W24. SOF/VEL. >. 18 years. Chronic HCV infection. Genotype 1 to 6. Naïve or treatment-experienced. No prior treatment with . NS5A or NS5B inhibitor. Child-Pugh B cirrhosis **. No . hepatocellular. HCV . GT 1,4, or 6 in PWID* on Opiate Agonist Therapy. C-EDGE CO-STAR. Phase . 2. Treatment. . Naïve. Dore G, . et al. . AALSD. 2015; Abstract 40. . Injection Drug Use. *PWID = Persons . W. ho . I.